Introduction to CDK 4/6 Inhibitor Drugs
CDK inhibitor drugs, also known as CDK (cyclin-dependent kinase) inhibitor is a type of chemical that restricts the function of CDKs. CDK 4/6 inhibitors are a class of drugs, also called (CDK4 and CDK6) that target enzymes. These enzymes are crucial in cell division. CDK 4/6 inhibitor plays a key role in regulating the replication and growth of breast cancer cells. The CDK 4/6 inhibitor drugs such as Palbociclib, Ribociclib, and Abemaciclib are used to treat metastatic breast cancer at an early stage.
Market Size and Forecast
Rising cases of patients with breast cancer owing to increasing exposure to risk factors such as carcinogens, sedentary lifestyles and pollution are the significant factors boosting the market growth. According to the statistics by the World Health Organization (WHO), it is estimated that 627000 women died from breast cancer in the year 2018. The growing concern for breast cancer globally and the need for treating such diseases are further anticipated to promote towards the growth of the global CDK 4/6 inhibitor drugs market. The CDK 4/6 inhibitor drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by end user into hospitals, clinics, research laboratories and retail pharmacies. Among these segments, the segment for hospitals is anticipated to hold the leading share in the market on account of availability of CDK 4/6 inhibitor drugs used for the patient’s treatment only at the hospital. The global CDK 4/6 inhibitor drugs market is further segmented by route of administration into inhaled, tablet, liquid and injection, out of which, the injection segment is anticipated to hold the largest market share owing to the increasing use of injections for treating breast cancer diseases. Healthcare specialists often prescribe the use of injections for delivering cancer drugs as it possesses numerous benefits over other dosage forms. Moreover, drug delivery through injections have been proved to be much more efficient as the drug is released directly to the blood stream in the body.
Rising Cases of Breast Cancer Globally to Boost the Market Growth
Breast cancer being the most common cancer among women, the need for advanced screening and treatment is increasing to cure it at an early stage. According to American Cancer Society, the chance that a woman will die from breast cancer is about 2.6% i.e. 1 in 38. The leading cause of high rates of cancer-related deaths in women is owing to the increased incidence of breast cancer. This factors attributes to the high demand for CDK 4/6 inhibitor drugs and is anticipated to significantly expand the CDK 4/6 inhibitor drugs market. CLICK TO DOWNLOAD SAMPLE REPORT
Huge Investment in Healthcare R&D to Drive the Market Growth
The healthcare development all over the world is improving at a fast pace owing to the increasing number of cases of various diseases which results in a growing demand for better healthcare services, facilities and equipment at clinics and hospitals. The growing research activities for treatment methods at research laboratories further fuels the healthcare industry. On the back of these, the market is predicted to grow over the forecast period.
High Cost and Side-Effects of Drugs to Hamper the Market Growth
Despite the improving healthcare infrastructure, there is a high cost involved with these drugs related to cancer treatment. Further, there are major side effects associated with this drugs post medication. This is estimated to hinder the growth of CDK 4/6 inhibitor drugs market in the future.
Our in-depth analysis of the CDK 4/6 inhibitor drugs market includes the following segments:
By Product Type
By Route of Administration
By End User
On the basis of regional analysis, the CDK 4/6 inhibitor drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for CDK 4/6 inhibitor drugs in North America is anticipated to hold the largest share in the market on account of presence of leading market players in the region which manufacture and market CDK 4/6 inhibitor drugs. Moreover, favorable reimbursement policies by the government in this region further increases the product demand. The market in Asia Pacific region is predicted to grow at the highest rate during the forecast period as a result of developing healthcare infrastructure and growing research activities in the region. Also, the rise in awareness about early diagnosis of diseases such as cancer in the region, especially in countries such as China, India and Japan further raise the demand for CDK 4/6 inhibitor drugs.
The CDK 4/6 inhibitor drugs market is further classified on the basis of region as follows:
Top Featured Companies Dominating the Market
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization